Press Releases

Latest News

Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy Is Well Tolerated In Phase 2a Study Of Immunocompromised Patients With Influenza A
Apr 28, 2010 | General Releases

Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible And Resistant Strains Of Influenza In Animal Models
Mar 15, 2010 | General Releases

Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy Is More Potent Than Double Combinations Or Monotherapy Against Drug-Resistant Flu Strains
Feb 22, 2010 | General Releases

Adamas Pharmaceuticals Raises $40 Million in Series D Financing
Aug 18, 2009 | Financial Releases

Adamas Pharmaceuticals Signs CRADA with U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including The Novel H1N1 Pandemic Strain
Aug 18, 2009 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10